Skip to main content

In Europe the growing demand for eye care services highlight shortage of ophthalmologists


The population of Europe is projected to become older in the coming decades, with an uneven growth rate expected in the various countries. The percentage of the total population age 65 years or older is predicted to increase from 17% in 2008 to 23.5% in 2030.
According to the EUREYE study, 3.3% of the European population age 65 years or older has AMD. The prevalence is 40% higher in women than men and rises steeply with age. This indicates approximately 2.5 million AMD cases within the 27 EU nations.
Data from the International Diabetes Federation show that there are currently 55 million adults and 112,000 children with diabetes in Europe; 10 million to 12 million more cases are expected by 2030.

Comments

  1. Amy Watson12 November 2018 at 19:30

    Retinitis pigmentosa is a chronic disease of the eye. The symptoms of this disease are night blindness, reducing the vision, blurry vision etc. This disease can be controlled by the treatment. The stem cell therapy is the best treatment for this disease. Retinitis pigmentosa treatment

    ReplyDelete

Post a Comment

Popular posts from this blog

Retina and Retinal Disorders The retina is a layer of tissue present in the interior of your eye.   Retina    disorders   are mainly due to lack of light-delicate cells and other nerve cells which transform the impulse into visual information. Retina sends this visual data to the cerebrum through your optic nerve and process the information into an image and empowering you to see. Different age group generations, races and ethnicities are effected from   Retinal degenerative disorders , for instance,   Age-related macular degeneration   and   myopic macular degeneration . Click here to submit your abstract for the Retina session:
2 comments
Read more
NEI Statistics
1 comment
Read more
(Reuters) - Aerie Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration approved its eyedrop, Rhopressa, as a treatment for glaucoma, two months ahead of the expected date. Glaucoma affects about 2.7 million people in the United States and is the second leading cause of blindness in the world. Rhopressa helps lower the pressure due to a build up of fluid in the eye by targeting the trabecular meshwork, the main drain through which fluid flows out of the eye. For more details:  New breakthrough in ophthalmology
2 comments
Read more